BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

CapitalBio Technology raises over $113M in pre-IPO round CapitalBio Corp. subsidiary CapitalBio Technology Co Ltd. raised over RMB800 million ($113 million) in a pre-IPO financing round last week led by Guangdong Boyi Design Institute Co....
BioCentury | May 6, 2020
Product Development

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

Novo Nordisk disclosed top-line Phase II data in NASH for semaglutide that puts the GLP-1 agonist in pole position with respect to mechanisms addressing NASH resolution. The readout came as Novo Nordisk A/S (CSE:NOVO B;...
BioCentury | Dec 17, 2019
Company News

Dec. 16 Company Quick Takes: Greenlight for Roche-Spark deal; plus BMS, Gilead, BioMarin, FDA guidance

Roche cleared to complete Spark takeover The planned merger of Roche (SIX:ROG; OTCQX:RHHBY) and Spark Therapeutics Inc. (NASDAQ:ONCE) has at last been cleared by the U.S. Federal Trade Commission and U.K. Competition and Markets Authority....
BioCentury | Nov 27, 2019
Product Development

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos

Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone...
BioCentury | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory...
BioCentury | Jul 19, 2019
Tools & Techniques

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...
BioCentury | Jul 2, 2019
Company News

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy...
BioCentury | Apr 25, 2019
Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
Items per page:
1 - 10 of 159